eTable. Summary of SCID newborn screening methods and definitions of T cell lymphopenia in different states
Customize your JAMA Network experience by selecting one or more topics from the list below.
Kwan A, Abraham RS, Currier R, et al. Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. JAMA. 2014;312(7):729–738. doi:10.1001/jama.2014.9132
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Newborn screening for severe combined immunodeficiency (SCID) using assays to detect T-cell receptor excision circles (TRECs) began in Wisconsin in 2008, and SCID was added to the national recommended uniform panel for newborn screened disorders in 2010. Currently 23 states, the District of Columbia, and the Navajo Nation conduct population-wide newborn screening for SCID. The incidence of SCID is estimated at 1 in 100 000 births.
To present data from a spectrum of SCID newborn screening programs, establish population-based incidence for SCID and other conditions with T-cell lymphopenia, and document early institution of effective treatments.
Epidemiological and retrospective observational study.
Representatives in states conducting SCID newborn screening were invited to submit their SCID screening algorithms, test performance data, and deidentified clinical and laboratory information regarding infants screened and cases with nonnormal results. Infants born from the start of each participating program from January 2008 through the most recent evaluable date prior to July 2013 were included. Representatives from 10 states plus the Navajo Area Indian Health Service contributed data from 3 030 083 newborns screened with a TREC test.
Main Outcomes and Measures
Infants with SCID and other diagnoses of T-cell lymphopenia were classified. Incidence and, where possible, etiologies were determined. Interventions and survival were tracked.
Screening detected 52 cases of typical SCID, leaky SCID, and Omenn syndrome, affecting 1 in 58 000 infants (95% CI, 1/46 000-1/80 000). Survival of SCID-affected infants through their diagnosis and immune reconstitution was 87% (45/52), 92% (45/49) for infants who received transplantation, enzyme replacement, and/or gene therapy. Additional interventions for SCID and non-SCID T-cell lymphopenia included immunoglobulin infusions, preventive antibiotics, and avoidance of live vaccines. Variations in definitions and follow-up practices influenced the rates of detection of non-SCID T-cell lymphopenia.
Conclusions and Relevance
Newborn screening in 11 programs in the United States identified SCID in 1 in 58 000 infants, with high survival. The usefulness of detection of non-SCID T-cell lymphopenias by the same screening remains to be determined.
The purpose of newborn screening is early detection of inborn conditions for which prompt treatments mitigate mortality or irreversible damage. The first heritable immune disorders to which newborn screening has been applied are those that together comprise severe combined immunodeficiency (SCID), caused by defects in any of a diverse group of gene products essential for development of adaptive immunity provided by T and B lymphocytes.1,2 A feature of all SCID is defective production of T cells. In most SCID, B cells are also defective, but even normal B cells cannot produce antibodies without T-cell help. Thus, infants with SCID are susceptible to life-threatening infections. Early detection and treatment optimize survival.3-5 Provided that SCID is diagnosed before infections become overwhelming, affected infants can be rescued with hematopoietic stem cell transplantation; gene therapy; or, for adenosine deaminase deficiency, enzyme replacement therapy.2,5-8
Population-based screening is the only means to detect SCID prior to the onset of infections in most cases, as more than 80% lack a positive family history.9,10 T-cell receptor excision circles (TRECs), a biomarker for T lymphopoiesis,11 can be measured by polymerase chain reaction (PCR) using DNA isolated from infant dried blood spots collected for newborn screening.9 Dried blood spots from apparently healthy newborns who were later diagnosed with SCID lacked TRECs.9 Confirmation of the utility of the TREC test,12 adaptation for pilot newborn screening programs in Wisconsin13 and Massachusetts,14 and an evidence-based review led to the recommendation by the US Department of Health and Human Services Secretary in 2010 that SCID be added to the Uniform Screening Panel for all newborns, with related T-cell deficiencies added to the list of secondary targets.15 Currently, 23 states, the District of Columbia, and the Navajo Nation screen approximately two-thirds of all infants born in the United States for SCID. Individual states have confirmed detection of SCID as well as additional disorders with low T-cell numbers, which also may benefit from further assessment of immune dysfunction and from protective treatments.13,16-18 Here we present the first combined analysis of more than 3 million infants screened for SCID in 10 states and the Navajo Nation, providing a population-based overview of SCID and non-SCID T-cell lymphopenia.
All SCID newborn screening programs active as of July 31, 2013, were invited, and 11 provided data for this study with the following accrual dates: California (August 16, 2010, to May 31, 2013), Colorado (February 1, 2012, to March 31, 2013), Connecticut (October 1, 2011, to May 1, 2013), Delaware (July 6, 2012, to June 30, 2013), Massachusetts (February 1, 2009, to January 31, 2013), Michigan (October 1, 2011, to March 31, 2013), Mississippi (January 1, 2012, to December 31, 2012), New York (September 29, 2010, to September 28, 2012), Texas (December 1, 2012, to May 31, 2013), Wisconsin (January 1, 2008, to December 31, 2012), and the Navajo Nation spanning parts of Arizona, New Mexico, and Utah, where health care is provided through the Navajo Area Indian Health Service (February 1, 2012, to June 30, 2013). Five states had insufficient data due to short SCID screening program duration: Iowa began June 3, 2013, and had fewer than 3000 births screened by the close of our study, based on published summaries of national vital statistics19; Pennsylvania, Utah, and Wyoming began July 1, 2013; and Ohio began July 29, 2013; thus, these states had no screened births prior to the close of our study. Florida started screening October 1, 2012, and screened an estimated 160 000 infants for SCID during the study period while Minnesota started January 7, 2013, accruing data for around 33 000 infants during the study period. In both states an administrative decision not to participate was made based on programmatic constraints. An estimated maximum of 196 000 screened births could have been included in the study if all programs had participated (a 6.5% increase above the total included in the 11 participating programs).19 All programs, whether participating in the study or not, conformed to the approved guidelines for implementation of SCID screening developed by the Clinical and Laboratory Standards Institute.20
Institutional review board approvals for research with human subjects or waivers for submitting data for this study were obtained in accord with requirements of each participating program. Deidentified SCID screening information was captured either via the R4S database,21 a tool for quality improvement of newborn screening supported by the Newborn Screening Translational Research Network, or via electronic spreadsheets. As defined in Table 1, typical SCID, leaky SCID, and Omenn syndrome, which require immune system restoration for survival, were the primary targets of SCID screening, while additional diagnoses were detected as secondary targets.5,20,22 Infants with abnormal TREC results had flow cytometry to enumerate lymphocyte subsets; HIV PCR or maternal serodiagnosis; and further evaluation to establish a diagnosis. To ensure follow-up and ascertainment of SCID cases, public health programs engaged as advisors the immunologists and transplant clinicians who have diagnosed and cared for infants with SCID in each state. Regular reviews were conducted between public health personnel and clinical experts in each program to uncover any missed (false-negative) cases and monitor screening test performance and follow-up.
Programs provided accrual dates, numbers of newborns screened, and data about infants with nonnormal TREC results (after 1 or multiple dried blood spot samples) in each diagnosis category. State-designated immunologists provided deidentified data in consultation with screening program officials to ensure compliance with privacy policies. Gene and syndrome diagnoses were requested. Numbers of infants with T cells within designated ranges and interventions and outcomes were reported by public health programs and by participating immunologists who evaluated and followed up or referred infants for treatment.
See the eMethods and eTable in the Supplement for individual program details beyond those published.13,14,17,18,20 All programs conformed to the guidelines that included reporting any nonnormal TREC test results within the first 3 weeks of life and performing flow cytometry, where indicated, by 4 to 5 weeks of age. In addition, all programs participated in the TREC Proficiency Quality Assurance Program, cosponsored by the Centers for Disease Control and Prevention and the Association of Public Health Laboratories.23
Statistical analyses were conducted in SAS version 9.3 (SAS Institute). Confidence intervals were derived from normal approximation of binomial data or from inversion of cumulative binomial distribution, as appropriate, but not calculated where numbers were too small. Confidence intervals were 2-sided, except that when the number of cases or noncases was 5 or fewer, 1-sided intervals were calculated. P values less than .05 were considered statistically significant.
This study included data for 3 030 083 infants from 11 programs (Table 2). Nonparticipating programs cited insufficient data, lack of personnel to assemble data, or privacy concerns. California, with nearly 3 years of screening and 12.5% of all US births,23 contributed 46%, followed by New York with 16% from 2 years. Wisconsin and Massachusetts, with fewer annual births but longer program durations, contributed 11% and 10%, respectively.
There were 52 SCID cases (42 with typical SCID, 9 with leaky SCID, and 1 with Omenn Syndrome), an overall incidence of 1 in 58 000 births (95% CI, 1/46 000-1/80 000) (Table 2). The incidence was not significantly different in any state program but as expected was higher in the Navajo Nation (1/3500; 95% CI, 1/630-1/4000), where a frequent founder mutation in DCLRE1C, encoding a DNA repair protein, causes SCID in an estimated 1 in 2000 births.24,25 No cases of SCID as defined in Table 1 were initially missed by TREC screening but detected later, and overdiagnosis of SCID when not clinically present was avoided by having flow cytometric determination of T-cell numbers, a definitive test, mandated for all infants with very low or undetectable TRECs (eTable in the Supplement).
Genetic causes and outcomes of the 52 infants with conditions that were primary targets of TREC newborn screening are shown in Table 3 and included 42 infants (81%) with typical and 10 (19%) with leaky SCID. Mutations in the X chromosome–linked IL2RG gene, encoding the cytokine receptor common γ chain, accounted for only 19% of cases. Recombinase activating gene 1 (RAG1) defects, causing impairment of V(D)J lymphocyte antigen receptor recombination, were detected in 4 typical and 4 leaky SCID cases, 1 of the latter with Omenn syndrome, accounting for 15% of all 52 cases. Interleukin-7 defects and adenosine deaminase deficiency contributed 12% and 11%, respectively. New SCID gene defects included mutations of tetratricopeptide repeat domain 7A (TTC7A) that disrupted not only T-cell development, but also intestinal epithelial polarity, leading to multiple bowel atresias.26,27 In addition, typical SCID was diagnosed in a case of Pallister-Killian syndrome, in which congenital diaphragmatic defects associated with tetrasomy 12p are frequently incompatible with life, as in this case. Although not previously recognized as an immune deficiency, Pallister-Killian syndrome has been known for poor lymphocyte proliferation in the context of cytogenetic analysis.28
Of the 12 infants without a molecular diagnosis, no gene test results were available for 2, and 2 males with T−B+NK− phenotype died prior to testing (Table 3). However, in 6 typical and 2 leaky SCID cases (15% of all typical and leaky SCID cases found), no molecular defects were identified in known SCID genes: the common γ chain or interleukin-7 receptors, adenosine deaminase or purine nucleoside phosphorylase enzymes, janus kinase-3, recombinase activating genes, the DNA repair enzyme Artemis, or components of the CD3 receptor complex.
Although all programs identified SCID cases with undetectable or very low TRECs, differences in intermediate steps for arriving at a SCID diagnosis influenced rates of follow-up testing and capture of non-SCID conditions (Table 1 and Table 4).20 After an abnormal TREC screen, flow cytometry to enumerate T, B, and NK cells, as well as naive and memory phenotype T cells, was standard for all programs. However, different TREC cutoffs resulted in different referral rates for flow cytometry; therefore, neither aggregate analysis nor interprogram comparison of incidences of infants with particular TREC cutoff values was possible. Rates of referral for flow cytometry were less than 15 per 100 000 in California, Colorado, and Mississippi but 7- to 9-fold higher in New York and Texas (Table 4).
Furthermore, definitions of T-cell lymphopenia varied. Healthy newborns have abundant T cells (mean, 3100/μL; range, 2500-5500).29 While 6 screening programs defined significant T-cell lymphopenia as T-cell count less than 1500/μL and opted not to recall infants with higher T-cell numbers as long as the proportion of naive cells was adequate, 4 programs used T-cell cutoffs of 2500/μL or more, and New York left it to individual immunologists to define T-cell lymphopenia.30 Different TREC and T-cell lymphopenia cutoffs thus resulted in variable false-positive rates, defined here as nonnormal TREC results that require a follow-up flow cytometry test, which when performed shows T cells above the program cutoff for T-cell lymphopenia (Table 4). These false-positive rates ranged from 0 in Mississippi and the Navajo Nation, where all infants referred to flow cytometry had T-cell lymphopenia by program definitions (<2500/μL and <1500/μL, respectively), to 82% in New York, where 478 infants were referred for flow cytometry, but only 84 (18%) had T-cell lymphopenia as determined by treating physicians (Table 4). A subgroup analysis for the 6 programs defining T-cell lymphopenia as a T-cell count less than 1500/μL showed a positive predictive value of 36% (95% CI, 32%-41%) for a nonnormal TREC test to indicate this degree of T-cell lymphopenia.
Regardless of selected T-cell lymphopenia cutoff, all programs identified predominantly male infants; the 6-program subgroup had 66% of males with T-cell lymphopenia (95% CI, 59%-73%). Programs did not report preterm infants with low T cells in a uniform manner, partly due to automatically repeated TREC testing of preterm infants in neonatal intensive care units in some screening programs (eMethods in the Supplement). However, 13% (95% CI, 8.4%-18%) of infants with T-cell lymphopenia in the 6-state subgroup had prematurity or low birth weight as the only identified cause. As previously reported, T-cell lymphopenia of prematurity resolved to normal over time.13,18 After excluding infants with SCID and prematurity, the rate of non-SCID T-cell lymphopenia in the subgroup was 1 in 14 000 infants (95% CI, 1/11 600-1/16 400), whereas more inclusive definitions led to 1 in 2100 in Michigan, 1 in 6500 in Massachusetts and New York, and 1 in 8100 in Wisconsin (Table 4).
Of 411 infants with non-SCID T-cell lymphopenia (Table 1 and Table 5), 136 (33%) were reported to have a recognized congenital syndrome associated with T-cell impairment. Of these syndromic infants, 78 (57%) had DiGeorge syndrome/chromosome 22q11.2 deletion, followed by 21 (15%) with trisomy 21. The remaining specified syndrome diagnoses included repeated instances of ataxia telangiectasia31 and trisomy 18 (each 3%), CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital and ear abnormalities) syndrome (2%), and other rare entities as listed (Table 5).32
There were 117 cases of T-cell lymphopenia attributed to other medical conditions (28% of all non-SCID T-cell lymphopenia cases) (Table 5), the most predominant being congenital heart disease in 30 cases (26%), followed by other congenital anomalies, vascular leakage and hydrops (grouped as loss into third space), gastrointestinal anomalies including gastroschisis, and 4 neonatal leukemias. No cases of HIV infection were detected.
Idiopathic T-cell lymphopenia, also termed variant SCID, was found in only 3% of non-SCID T-cell lymphopenia cases (12/411, or 1/250 000 births); these infants did not meet the diagnostic criteria for leaky SCID but had persistent T-cell lymphopenia and immune dysfunction without defects in known SCID genes (Table 1).18,30 One of these 12 infants eventually required hematopoietic cell transplantation. The screening program in New York identified 30 further cases as having idiopathic T-cell lymphopenia,30 included in Table 5 among the unspecified T-cell lymphopenia cases because their T-cell counts were not available.
Of the 52 infants detected with SCID in the first weeks of life, 49 received immunity restoring therapies. Forty-four had hematopoietic cell transplants, 4 had gene correction of IL2RG and ADA defects by ex vivo transduction of a normal gene sequence into autologous hematopoietic stem cells (1 of whom required subsequent hematopoietic cell transplant due to inadequate correction), and 2 had adenosine deaminase enzyme injection therapy. In addition, non-SCID cases requiring immune restorative treatment included 1 infant with Rac2 deficiency (a syndrome of defective neutrophil adhesion) and 1 with variant SCID who received hematopoietic cell transplantation, and 2 infants with complete DiGeorge syndrome who received thymus transplantation (Table 3 and Table 5). Of 7 deaths among the 52 infants with typical SCID and leaky SCID, 3 were due to perinatal complications, including 1 with Pallister-Killian syndrome, 1 with intestinal malrotation and severe respiratory distress,30 and 1 with undescribed medical problems that precluded transport to a center where hematopoietic cell transplant could be done. Four infants with SCID died after transplant. Thus, overall SCID survival was 45 of 52 (87%), while 45 of 49 treated infants (92%) survived, comparable with experience from transplant centers for uninfected SCID patients treated early in life.4-7 Posttreatment deaths were due to cytomegalovirus infection acquired early postnatally in 1, pretransplant respiratory compromise in 1, and hepatic sinusoidal obstructive disease secondary to pretransplant busulfan chemotherapy in 2 (Table 3).
All infants with T-cell lymphopenia were directed to avoid infectious exposures, transfusions (except with cytomegalovirus-negative, irradiated blood products), and live rotavirus vaccines until such time as immune compromise was no longer present. Prophylactic antimicrobials and immunoglobulin infusions were given as indicated by immunology specialists.
To our knowledge, this is the first multistate report of results of newborn screening for SCID, a core condition in the US Recommended Uniform Screening Panel. Our experience has demonstrated the feasibility of assaying for TRECs, a biomarker for naive T-cell lymphopoiesis, followed by confirmatory flow cytometry, as a means to identify SCID. Newborn screening has provided a new, population-based incidence of SCID of 1 in 58 000 births, higher than the incidence of 1 in 100 000 suggested from retrospective clinical diagnoses.33-35 Furthermore, the proportion of IL2RG deficient X-linked SCID in our study (19%) is in contrast to nearly half of cases in published cohorts from referral centers that treat SCID.5-8 Because X-linked disorders with severe phenotype maintain constant frequency due to replenishment in the gene pool by new mutations,36 our lower proportion of IL2RG-deficient SCID is likely to reflect increased ascertainment of autosomal-recessive SCID cases by population-based screening. Moreover, compared with series from large transplant centers, in which less than 10% of cases lacked a molecular diagnosis,5,8 our newborn screened cases had a higher proportion of leaky SCID and more than 15% of typical and leaky SCID without a proven molecular diagnosis despite extensive gene sequencing (Table 3). These findings support the view that SCID has previously been underdiagnosed in infants with fatal infections. Furthermore, proportions of typical SCID, leaky SCID, and Omenn syndrome in our cohort appear distinct from those previously reported for older infants; features of Omenn syndrome develop over months after birth, and the clinical diagnosis of leaky SCID can be delayed for years.37
Additional data collection may reveal new demographic patterns, such as the known high Navajo incidence of SCID due to a DCLRE1C founder mutation and Amish and Mennonite founder mutations in ADA, IL7R, and RAG1.38,39 Inclusion of data from more SCID screening programs in additional states would be required to know if the results from the 11 participating programs included here are fully generalizable. Whether the excess of males with abnormal SCID newborn screens is explained by the known higher rate of male preterm births as well as the common X-linked SCID gene IL2RG also needs to be explored. The unanticipated high proportion of SCID without a defined genotype and new discovery of non-SCID T-cell lymphopenias illustrate how unbiased population screening reveals a wide phenotypic spectrum and affords opportunities to discover previously unknown genes essential to human T-cell development.
Now that infants with SCID are being detected at a very young age in diverse medical settings, it is imperative to tailor protocols for their treatment, including choice and pharmacokinetic monitoring of drugs administered to facilitate hematopoietic cell engraftment. Busulfan chemotherapy led to fatal hepatic sinusoidal obstruction, also known as veno-occlusive disease, in 2 infants diagnosed with SCID by newborn screening. Prospective studies conducted by the Primary Immune Deficiency Treatment Consortium will address whether dose adjustments based on age or alternate regimens will provide enhanced safety while still affording long-lasting immune reconstitution.5,8,21,40
A major limitation of this study was the lack of uniformity of assay methodology and rules for retesting among the individual newborn screening programs, despite general adherence to the Clinical and Laboratory Standards Institute guidelines.20 Use of different TREC assays and test algorithms resulted in a variety of rates both for recall for additional testing and for having T cells by flow cytometry in a range defined as normal. Specific information about the ages at which samples for TREC screening and for flow cytometry were obtained were not available. No program identified a false-negative test for SCID, the primary target condition. Furthermore, although the definitive flow cytometry test was universally used as follow-up for infants whose TRECs were not normal, different cutoffs were used to define non-SCID secondary targets of screening. Therefore, the incidence of T-cell lymphopenia cases referred for follow-up varied from 3 to 47 cases per 100 000 infants (Table 4).
While unsuspected non-SCID immunodeficiency syndromes were identified and 4 infants had immune defects sufficiently serious to require hematopoietic cell or thymus transplantation, these benefits must be weighed against the burdens of heightened parental anxiety and costs of further testing in infants with less profound T-cell lymphopenias. As with development of each newborn screening test since the original one for phenylketonuria,41 different initial approaches for SCID screening are anticipated to evolve and become standardized over time, as evident in adjustments to TREC screening algorithms that have already occurred.17,30 Specific data regarding persistence of non-SCID T-cell lymphopenia over time and functional T-cell abnormalities were not available for our analysis but should in the future be collected to clarify which infants require interventions, such as avoidance of live rotavirus vaccination, which can cause serious diarrheal disease in infants with immunodeficiency.42,43
Differences in cutoffs between the SCID screening programs in this study may prove helpful for public health programs in other states and countries considering instituting SCID newborn screening. In addition, the R4S SCID database will permit future analytical and clinical correlations to optimize cutoffs for key markers, such as T-cell numbers, to inform best practices.19,44
The TREC assay has proven excellent for detecting disorders with poor T-cell production or inadequate numbers of circulating T cells, but finding additional immune defects prior to onset of recurrent or life-threatening infections will require further methods. A few more entities may be captured by screening for the circular by-products of B-cell immunoglobulin gene rearrangement,45 and mild as well as severe cases of adenosine deaminase deficiency may be identified by a modification of the current mass spectrometry already widely used for newborn screening.46 However, infants with defects affecting T cells beyond the developmental stage of recombination of T-cell receptors (eg, major histocompatibility complex class II deficiency47) have normal TRECs but impaired T-cell function. Genomic sequencing may be required to detect deleterious mutations in primary immune defects, of which nearly 200 are known.1
Newborn screening in 11 programs in the United States identified SCID in 1 in 58 000 infants, with high survival. The usefulness of detection of non-SCID T-cell lymphopenias by the same screening remains to be determined.
Corresponding Author: Jennifer M. Puck, MD, Department of Pediatrics, HSE-301A, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143 (email@example.com).
Author Contributions: Drs Kwan and Puck had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Kwan and Abraham contributed equally to this work.
Study concept and design: Kwan, Abraham, Brower, Bonagura, Church, Comeau, Cowan, Lee, Lorey, Naides, Routes, Saavedra-Matiz, Secord, Shearer, Stiehm, Tanksley, Watson, Puck.
Acquisition, analysis, or interpretation of data: Kwan, Abraham, Currier, Brower, Andruszewski, Abbott, Baker, Ballow, Bartoshesky, Bonagura, Bonilla, Brokopp, Brooks, Caggana, Celestin, Church, Connelly, Cowan, Cunningham-Rundles, Dasu, Dave, De La Morena, Duffner, Fong, Forbes, Freedenberg, Gelfand, Hale, Hanson, Hay, Hu, Infante, Johnson, Kapoor, Kay, Kohn, Lehman, Lin, Lorey, Abdel-Mageed, Manning, McGhee, Moore, Naides, Notarangelo, Orange, Pai, Porteus, Rodriguez, Romberg, Routes, Ruehle, Rubenstein, Saavedra-Matiz, G. Scott, P. Scott, Secord, Seroogy, Shearer, Siegel, Silvers, Stiehm, Sugerman, Sullivan, Tierce, Verbsky, Vogel, Walker, Walkovich, Walter, Wasserman, Watson, Weinberg, Weiner, Wood, Yates, Puck.
Drafting of the manuscript: Kwan, Abraham, Baker, Bonagura, Gelfand, Kapoor, Abdel-Mageed, Manning, Routes, Rubenstein, P. Scott, Shearer, Sullivan, Walker, Puck.
Critical revision of the manuscript for important intellectual content: Kwan, Abraham, Currier, Brower, Andruszewski, Abbott, Ballow, Bartoshesky, Bonagura, Bonilla, Brokopp, Brooks, Caggana, Celestin, Church, Comeau, Connelly, Cowan, Cunningham-Rundles, Dasu, Dave, De La Morena, Duffner, Fong, Forbes, Freedenberg, Gelfand, Hale, Hanson, Hay, Hu, Infante, Johnson, Kay, Kohn, Lee, Lehman, Lin, Lorey, Abdel-Mageed, Manning, McGhee, Moore, Naides, Notarangelo, Orange, Pai, Porteus, Rodriguez, Romberg, Routes, Ruehle, Saavedra-Matiz, G. Scott, Secord, Seroogy, Shearer, Siegel, Silvers, Stiehm, Sugerman, Tanksley, Tierce, Verbsky, Vogel, Walkovich, Walter, Wasserman, Watson, Weinberg, Weiner, Wood, Yates, Puck.
Statistical analysis: Kwan, Abraham, Currier, Abbott, Hanson, Johnson, Kay, Lee, Lorey, Routes, G. Scott, P. Scott, Puck.
Obtained funding: Brower, Baker, Bonagura, Brokopp, Cowan, Lorey, Abdel-Mageed, Notarangelo, Routes, Watson, Puck.
Administrative, technical, or material support: Currier, Brower, Abbott, Baker, Ballow, Bartoshesky, Bonilla, Brokopp, Caggana, Celestin, Comeau, Connelly, Cunningham-Rundles, Dasu, Duffner, Forbes, Hale, Hay, Hu, Kapoor, Kohn, Lee, Lin, Lorey, Abdel-Mageed, Manning, Moore, Naides, Orange, Routes, Saavedra-Matiz, Shearer, Stiehm, Sugerman, Sullivan, Tanksley, Tierce, Walkovich, Walter, Watson, Weinberg, Wood, Puck.
Study supervision: Abraham, Baker, Bonagura, Caggana, Celestin, Comeau, Cowan, Gelfand, Infante, Lee, Lehman, Abdel-Mageed, Naides, Routes, Rubenstein, Saavedra-Matiz, Stiehm, Sullivan, Watson, Puck.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Bonagura reported receiving grants from the Jeffrey Modell Foundation, Baxter Pharmaceuticals, and New York State; serving on a committee for CSL-Behring; and serving on an advisory board for Baxter Pharmaceuticals. No other disclosures were reported.
Funding/Support: This study received support from the following institutions: in California: National Institutes of Health (NIH) (HHSN267200603430C through New York, R01 FD003005-01, U01 AI1087628 [D.B.K.]; RO1 AI078248, AI105776 [J.M.P.]); HCA International Foundation Travelling Scholarship (A.K.); Jeffrey Modell Foundation; and Perkin Elmer Genetics. In Colorado: Colorado Department of Public Heath and Environment. In Connecticut: state appropriation, pursuant to Public Act 11-48, Sections 38 and 39, which mandated the inclusion of testing for severe combined immunodeficiency (SCID) in the Connecticut Newborn Screening Disorders Panel and provided increased agency funding to accomplish this mandate. In Delaware: Centers for Disease Control and Prevention (CDC) (U01 EH000454) and state funding. In Massachusetts: CDC (U01 EH000362) and New England Newborn Screening Program funds. In Michigan: CDC (U01 EH000936). In Mississippi: Mississippi State Department of Health. In the Navajo Nation: NIH (RO3HD060311 [J.M.P.]) and a gift to Navajo-area delivering hospitals from PerkinElmer Genetics, Bridgeville, Pennsylvania. In New York: NIH (HHSN267200603430C), Jeffrey Modell Foundation, and New York State Department of Health. In Texas: CDC grant through New England Newborn Screening Program (pilot phase), Jeffrey Modell Foundation, and the Texas Department of State Health Services. In Wisconsin: Jeffery Modell Foundation, Children’s Hospital of Wisconsin, Wisconsin State Laboratory of Hygiene, CDC (U01 EH000365), and Primary Immunodeficiency Treatment Consortium (U54 A1082973 [M.J.C.], R13-A1094943 [M.J.C., L.D.N.]). The Newborn Screening Translational Research Network (NBSTRN) is a contract to the American College of Medical Genetics and Genomics by Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH (HHSN27520080001C).
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions:California: Vijaya Pasupuleti; Ryan Glaraga, BASc; Jerry D. Ramirez Jr; Zenaida Nakar, BS; Gloria Ramirez; Neil Lim, BS; Larry Eck, BS, Quest Nichols Institute, San Juan Capistrano. These individuals assisted with flow cytometry determination and reporting for the California Department of Public Health Newborn Screening Program. Colorado: Mark Dymerski, BS, Newborn Screening Unit, Colorado Department of Public Health and Environment, Denver, assisted with SCID screening and tracking of results. Connecticut: Odelya Pagovich, MD, Yale University, New Haven, assisted with follow-up of infants. New York: Jason Isabelle; April Parker; Lisa DiAntonio, MS; Allison Young; Victoria Popson, Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany. These individuals assisted with TREC testing and reporting in the New York State Newborn Screening Program. Michigan: Karen Dahl, MD, Helen De Vos Children’s Hospital, Grand Rapids, assisted with follow-up of infants. Mississippi: Phillis Hoggatt, RN, and Beryl Polk, PhD, Mississippi Department of Public Health, Jackson, assisted with sample tracking and reporting. Texas: Howard Rosenblatt, MD (Austin); Wesley Stafford, MD (Corpus Christi); Lyndon Mansfield, MD (El Paso); Susan Pacheco, MD (Houston); Todd Holman, MD (Longview); and Robert Mamlock, MD (Lubbock), assisted with follow-up of infants. Wisconsin: Mary Hintermeyer, APNP; Christine Bengtson, MS; Michael Cogley, BS; Lisa Berkan, MT; Marcy Rowe, BS, Wisconsin State Laboratory of Hygiene, University of Wisconsin, Madison and Milwaukee. These individuals assisted with TREC testing, reporting, and follow-up. R4S and NBSTRN: Piero Rinaldo, MD, PhD, Mayo Clinic, Rochester, MN, assisted with customizing the R4S database SCID module and analyzing data for this study. CDC Newborn Screening Branch, Atlanta, Georgia: Robert F. Vogt Jr, PhD, provided helpful comments and suggestions throughout. No compensation for the contribution was received by any person acknowledged here.
Correction: This article was corrected online August 20, 2014, and October 14, 2014.
Create a personal account or sign in to: